ADC Therapeutics Reports Higher Q1 Sales and Lower Costs as Zenlonta Readouts Near

Overview

• The company reported Q1 2026 net product revenue of $20 million, up 15% from a year ago.
• Operating expenses fell 13% versus Q1 2025 as management tightened spending.
• It ended the quarter with $231 million in cash, which the company says funds operations into 2028.
• Executives said they are in a quiet period and remain blinded to Lotus 5 efficacy data.
• Management projected a 2027 sales ramp only if Zenlonta trials succeed and regulators allow broader use, with data from Lotus 5, Lotus 7, and indolent lymphoma studies due in 2026–2027.